BioCentury | Jan 24, 2019
Emerging Company Profile

Caelus' microbes for metabolic syndrome

Of the handful of companies aiming to harness the therapeutic potential of the microbiome, Caelus Health is the first to reach the clinic with a bacterial therapeutic for metabolic syndrome: an oral formulation of Eubacterium...
BC Week In Review | Feb 3, 2017
Company News

J&J, Caelus deal

Caelus joined Johnson & Johnson’s Belgium-based JLINX incubator and will gain access to the computational resources of J&J’s Janssen Human Microbiome Institute (JHMI) for use in identifying potential microbiome-based therapies. Caelus’ lead candidate, CP-001 , is...
BC Extra | Feb 2, 2017
Company News

Caelus investment among J&J's microbiome deals

The Janssen Human Microbiome Institute (JHMI) of Johnson & Johnson (NYSE:JNJ) announced three microbiome-related deals Thursday, including an equity investment in cardiometabolic company Caelus Health (Amsterdam, the Netherlands). J&J’s Johnson & Johnson Innovation-JJDC Inc. venture...
Items per page:
1 - 3 of 3